[김창수의 e뉴스 브리핑] Celltrion antibody treatment’Rekirona’ started supplying nationwide medical institutions

[FETV=김창수 기자] Korea’s first COVID-19 antibody treatment,’Rekirona’, which was conditionally approved by the Ministry of Food and Drug Safety, will be supplied to medical institutions from the 17th. On the 17th, Hanmi Pharmaceutical made an internal announcement that one employee working at the 13th floor of the headquarters had been diagnosed with Corona 19 on the morning of that day. Kwangdong Pharmaceutical has launched a new pouch formulation for the preparation of ivy leaf ingredient Jinhae Expectant’Furosphan Syrup’.

◆ Celltrion antibody treatment’Rekirona’ started supplying nationwide medical institutions

Korea’s first COVID-19 antibody treatment,’Rekirona’, which was conditionally approved by the Ministry of Food and Drug Safety, will be supplied to medical institutions from the 17th.

Celltrion began accepting supply applications for each medical institution on the 16th, and starting with the medical institution that submitted the supply application on the first day of receipt, the supply will begin in earnest today. Celltrion Pharmaceutical, a subsidiary that has the right to supply Celltrion antibody drugs in Korea, will supply Rekirona in Korea.

The treatment is provided free of charge to patients and can be supplied by filling out a supply request form directly from 156 designated Corona 19 treatment medical institutions nationwide and applying to Celltrion Pharmaceutical. Celltrion Pharmaceutical will immediately deliver the medicine to the relevant medical institution after confirming the requested supply request. In addition, after dispensing drugs, the drug dispensing status is written and submitted to the Korea Centers for Disease Control and Prevention, and the Agency plans to manage the inventory management and medication status of the treatment.

◆ Hanmi Pharmaceutical Headquarters confirmed one corona19… Returning home and inspection measures

One confirmed case of a novel coronavirus infection (Corona 19) occurred at Hanmi Pharmaceutical’s headquarters in Songpa-gu, Seoul.

According to the pharmaceutical industry on the 17th, Hanmi Pharmaceutical announced to the inside that one employee working on the 13th floor of the headquarters had been diagnosed with Corona 19 this morning. This employee worked from the 15th this week to the morning of the 16th, the previous day.

An official from Hanmi Pharm said, “It is difficult to confirm which department the employee is in under the Personal Information Protection Act.”

In response to the outbreak of corona 19 confirmed, Hanmi Pharmaceutical will take all employees on the 13th floor home and conduct tests at a screening clinic.

◆ Kwangdong Pharmaceutical launches Jinhae expectorant’Purosphan Syrup’ pouch

Kwangdong Pharmaceutical has launched a new pouch formulation for the preparation of ivy leaf ingredient Jinhae Expectant’Furosphan Syrup’.

Purosphan syrup is an original product developed by Engelhart, Germany, as a herbal ingredient, and has been used for 40 million cases per year (as of 2019) in 90 countries around the world since its first commercialization in 1950, and is exclusively supplied by Kwangdong Pharmaceutical in Korea.

Previously, this product was only covered by health insurance benefits for under 12 years of age, but due to the change in the wage standard in February 2019, it has become possible to prescribe benefits for adults. Since then, as the demand for various formulations has increased, Kwangdong Pharmaceutical will launch additional pouch formulations for preparation. Currently, Furosphan Syrup consists of the existing 200ml bottle product and the newly released 7.5ml pouch type product, and has a product line that considers the convenience of taking both children and adults.

◆ “Another 4th generation skin booster introduced”… ID Dermatology begins Refileo treatment

ID Dermatology introduces the 4th generation skin booster’Refileo DMT’ (hereinafter referred to as Refileo) containing human stem cell culture fluid and begins treatment. It seems that the demand for skin boosters has increased due to the need for simple procedures and the cause of troubles caused by wearing a mask.

According to ID Dermatology on the 17th, Refileo is a new concept collagen skin booster that gives fundamental vitality by promoting collagen synthesis and inducing skin cell regeneration. If a general skin booster merely supplies nutrients, Refileo is characterized by high sustainability by creating an environment that enhances collagen production.

In fact, Refileo contains’JCER Complex (collagen growth factor + 9 growth factors)’, an exclusive synthetic substance of JCree Company, which participates in development and supplies products. The substance is composed of CPF (collagen growth factor) and 9 multi-peptides in which two or more amino acids are bound.

◆ Biodyne acquires additional US patents for Blowing Technology… Expand technology protection

Biodyne, a manufacturer of early cancer detection equipment and diagnostic reagent kits, announced on the 17th that it obtained a US patent in the Apparatus related to blowing technology last year, and then acquired a US patent in the method. .

The invention name of the US patent registered this time is “Methods for providing objects to be medically examined by blowing” (registration number US10895729B2), which is a patent related to the existing “Apparatus for providing object to be medically examined by blowing” (registration number US10520405B2). .

An official from Biodyne said, “The patents registered this time work together with previously registered patents to further broaden the scope of claims in the United States. Accordingly, the barriers to market entry of competitors as well as the barriers to technology protection of Biodyne have been greatly increased. “In addition, in the United States, where patent registration is more difficult, such as requiring the submission of investigation details (IDs) for precedent patents, the broadening of claims for’Blowing Technology’ means that it can be a precedent in other countries as well. Is very big.”